A new revolutionary blood test has been developed that can detect minute traces of a deadly form of cancer known as pancreatic cancer. This highly sensitive test targets a crucial genetic mutation, KRAS, which is responsible for more than 90% of pancreatic cancer cases, a mutation often missed by traditional screening methods.
Researchers at Northwestern University Feinberg School of Medicine in Chicago conducted a study where blood samples from patients with localized pancreatic cancer were analyzed using this advanced blood test. The test successfully identified cancer indicators in 65% of patients at the time of diagnosis, a significant improvement compared to the standard test, which only detected cancer in 17% of cases.
Even after chemotherapy and surgery, the sensitive blood test continued to detect residual cancer that imaging techniques failed to identify. This breakthrough research, detailed in the journal Clinical Cancer Research, coincides with the development of a new drug targeting the KRAS mutation, showing promising results in extending patients’ survival.
Professor Akhil Chawla, the lead author of the study, emphasized the importance of this new screening tool in tracking the KRAS mutation, particularly as new therapies targeting this mutation are emerging. This combined approach could revolutionize how high-risk patients are identified, enable monitoring of microscopic disease, and potentially lead to earlier interventions before cancer recurrence becomes apparent, ultimately increasing the number of patients achieving a cure.
Pancreatic cancer is one of the deadliest forms of cancer, often recurring even after extensive treatment. The study’s findings shed light on the challenges in detecting low levels of circulating tumor DNA and the need for more precise monitoring tools to assess treatment effectiveness.
The study followed 106 patients with localized pancreatic cancer, analyzing blood samples using digital droplet PCR (ddPCR), a more sensitive test compared to the conventional next-generation sequencing tests (NGS). Results showed that ddPCR outperformed NGS in detecting cancer indicators both at diagnosis and post-treatment, identifying a group of high-risk patients who were missed by standard testing methods.
Improved detection accuracy with ddPCR led to better predictions of survival outcomes, highlighting the importance of early cancer detection through liquid biopsies. These blood tests can detect traces of tumor DNA in the bloodstream, providing crucial information on cancer presence or potential recurrence without invasive procedures.
These significant findings show the potential of advanced blood tests like ddPCR in transforming cancer diagnosis and management, offering new hope for patients battling pancreatic cancer.